1. HBW Insight
  2. >>Health
  3. >>Innovation & IP

RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation

 
• By Tom Gallen

With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.

Create New Products Concept - Modern Keyboard with Button. Selective Focus on the Create New Products Keypad. Hand Finger Press Create New Products Keypad. 3D Render.
• Source: Shutterstock

Reckitt Benckiser is doubling its spend on OTC drug research and development as it looks to turn around this ailing part of its Health business.

Speaking as the UK-based health and hygiene player reported OTC sales down 3% in 2020, CFO Jeff Carr said RB...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation & IP

GSCF: ‘No One Size Fits All’ Solution To Tricky Sustainable Blister Pack Challenge

 
• By David Ridley

A series of research papers recently published by the Global Self-Care Federation indicate that industry will need to be pragmatic about alternatives to PVC in medicine blister packs.

Maternal Nutrition, Contraceptive Innovation Among Gates Foundation’s Latest Research Goals

 
• By Malcolm Spicer

“Women’s health continues to be ignored, underfunded, and sidelined. Too many women still die from preventable causes or live in poor health. That must change,” says Bill Gates.

Over The Counter: Seizing The Healthy Aging Opportunity, With Prime Fifty’s Max Gowland

 
• By David Ridley

HBW Insight speaks to Prime Fifty founder and managing director Max Gowland about the science behind healthy aging and the opportunity for the consumer health industry.

German Switch Committee Supports OTC Melatonin And Acyclovir, Rejects Rupatadine

 
• By David Ridley

Germany’s Expert Committee for Prescription supports the Rx-to-OTC switches of melatonin and buccal acyclovir but rejects rupatadine.

More from Health

Moberg Has US Ambitions For Novel Nail Fungus Treatment

 
• By Tom Gallen

Sweden's Moberg wants to introduce its onychomycosis treatment to the US but expects it will need to complete an additional study to win FDA approval.

Maternal Nutrition, Contraceptive Innovation Among Gates Foundation’s Latest Research Goals

 
• By Malcolm Spicer

“Women’s health continues to be ignored, underfunded, and sidelined. Too many women still die from preventable causes or live in poor health. That must change,” says Bill Gates.

New US FDA Chief Counsel More Familiar With Trump World Than Food and Drug Law

 
• By Sarah Karlin-Smith

Sean Keveney is largely unknown in the FDA law space, but likely is familiar and connected to the White House given his work on Trump’s antisemitism taskforce.